Why Is Capricor Therapeutics, Inc. (CAPR) Stock Down -12% Today?
Key Takeaways
- CAPR shares fell approximately 11.5% intraday amid heightened regulatory scrutiny.
- The primary catalyst was the FDA’s announcement scheduling an advisory committee meeting for Deramiocel’s Biologics License Application.
- Positive five-year clinical data for the Duchenne muscular dystrophy therapy failed to offset investor concerns over the upcoming review.
- Broader biotech sector weakness and profit-taking after recent gains amplified the decline.
- Traders are now focused on the July 29 advisory committee meeting and the August 22 PDUFA target action date.
Opening Summary
Capricor Therapeutics, Inc. (CAPR) is a clinical-stage biotechnology company focused on developing cell and exosome-based therapies for rare diseases, with its lead candidate Deramiocel targeting cardiomyopathy associated with Duchenne muscular dystrophy. Shares declined sharply in today’s session, falling roughly 11.5% from the prior close of $29.51 to trade near $26.91. The move reflects market reaction to fresh regulatory developments rather than a change in the company’s fundamental clinical progress.
**
Regulatory Catalyst: FDA Advisory Committee Meeting
The U.S. Food and Drug Administration scheduled an advisory committee meeting for July 29, 2026, to review Capricor’s Biologics License Application for Deramiocel. While such meetings provide an opportunity to present data, they also introduce an additional layer of public scrutiny and potential for debate on clinical endpoints. Investors interpreted the announcement as a signal of heightened review intensity ahead of the August 22, 2026 PDUFA target action date, triggering immediate selling pressure despite the company’s recent presentation of positive five-year open-label extension data from the HOPE-2 trial and Phase 3 HOPE-3 results.
**
Clinical Data Context and Market Reaction
Capricor simultaneously highlighted encouraging long-term muscle and cardiac function outcomes at the PPMD 2026 Annual Conference. However, the regulatory milestone overshadowed the positive clinical updates. The stock’s sharp reversal illustrates how binary regulatory events can dominate price action even when underlying trial results remain supportive. Volume increased notably compared with recent averages, indicating broad participation in the move.
Market Context and Trading Activity
The decline occurred against a backdrop of mixed broader biotech performance and modest gains in major indices. CAPR decoupled from sector peers as the company-specific news dominated sentiment. Technical levels near recent highs gave way, with the stock breaking below short-term moving averages amid the selloff. Elevated trading activity relative to the 30-day average confirmed the move carried conviction rather than reflecting thin liquidity.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the platform’s strongest-performing AI trading bots under current market conditions. Tickeron offers hundreds of AI-driven trading bots across thousands of symbols and strategies, but only those demonstrating the best risk-adjusted performance metrics in the prevailing environment are featured in the curated Trending section. Bots differ by time horizon, signal generation approach, and the specific equities or assets they trade. Investors seeking automated, data-driven exposure to names such as CAPR can explore the live rankings and performance statistics on the page.
What Comes Next for CAPR
Attention now turns to the July 29 advisory committee meeting and any additional information requests from the FDA ahead of the August 22 PDUFA date. The company continues to advance manufacturing preparations and address commercial considerations, including an ongoing legal matter with its former distributor that does not affect the regulatory timeline. Key risks include the outcome of the advisory vote, potential labeling limitations, and overall market volatility in the biotechnology sector. No material changes to the review clock have been indicated to date.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
CAPR in upward trend: price expected to rise as it breaks its lower Bollinger Band on October 05, 2026
CAPR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 32 of 33 cases where CAPR's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The 10-day moving average for CAPR crossed bullishly above the 50-day moving average on September 25, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 14 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 88%.
Following a +6.14% 3-day Advance, the price is estimated to grow further. Considering data from situations where CAPR advanced for three days, in 228 of 275 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CAPR as a result. In 68 of 80 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.
The Moving Average Convergence Divergence Histogram (MACD) for CAPR turned negative on October 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 34 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 79%.
CAPR moved below its 50-day moving average on October 12, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CAPR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
The Aroon Indicator for CAPR entered a downward trend on October 07, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating steady price growth. CAPR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 82 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.057) is normal, around the industry mean (26.823). P/E Ratio (0.000) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (7.610) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (125.000) is also within normal values, averaging (438.009).
The Tickeron Profit vs. Risk Rating rating for this company is 92 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CAPR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Develops innovative products for the treatment of cardiovascular diseases
Industry Biotechnology
Advertisement